Early diagnosis of cardiac involvement in systemic sclerosis by 123i-mibg neurotransmitter scintigraphy

Nuclear Medicine Communications

Volumn 19, Issue 9, 1998, Pages 849-858

  GuRtner C ^a   Krause, Bernd Joachim ^a   HOR G ^a   Werner, R J ^a   Holzmann, H ^a   Winten, G ^a   Wendt, T ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; NEUROTRANSMITTER; NORADRENALIN;

ADRENERGIC SYSTEM; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE CLASSIFICATION; DRUG DISTRIBUTION; DRUG UPTAKE; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; EXERCISE TEST; FEMALE; HEART DISEASE; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE ISCHEMIA; HEART SCINTISCANNING; HOLTER MONITORING; HUMAN; IMAGE ANALYSIS; INTRAVENOUS DRUG ADMINISTRATION; MALE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMIC SCLEROSIS;

3-IODOBENZYLGUANIDINE; ADULT; AGED; ARRHYTHMIA; BIOLOGICAL TRANSPORT; FEMALE; HEART; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; PROGNOSIS; RADIOPHARMACEUTICALS; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0031731775     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1080/00006231-199809000-00005     Document Type: Article

References (56)

1. LeRoy EC. Pathogenesis of scleroderma (systemic sclerosis). J Invest Dermatol 1982; 79: 87-89.
2. Sternberg EM. Pathogenesis of scleroderma: The interrelationship of the immune and vascular hypothesis. Surv Immunol Res 1985; 4: 69-80.
3. Maricq HR. Raynaud’s phenomenon and microvascular abnormalities in scleroderma (systemic sclerosis). In: Jayson MIV, Black CM, eds. Systemic sclerosis: Scleroderma. New York: John Wiley, 1988: 151-166.
4. Bennett R, Bluestone R, Holt PJL, Bywaters EGL. Survival in scleroderma. Ann Rheum Dis 1971; 30: 581-588.
5. Medsger TA Jr, Masi AT, Rodnan GP, Benetek TG, Robinson H. Survival with systemic sclerosis (scleroderma). A life table analysis of clinical and demographic factors in 309 patients. Ann Intern Med 1971; 75: 369-376
6. Holzmann H, Jacobi V, Werner RJ, Stahl E. Lungenmanifestation der progressiven systemischen Sklerodermie. Com-putertomographische Befunde. Hautarzt 1994; 45: 471-475.
7. Bulkley BH, Ridolfi RL, Salyer WR, Hutchins GM. Myocardial lesions of progressive systemic sclerosis: A cause of cardiac dysfunction. Circulation 1976; 53: 483-490.
8. Weiner SR, Clements PJ. Scleroderma heart disease. In Jayson MIV, Black CM, eds. Systemic sclerosis: Scleroderma. New York: John Wiley, 1988: 207-220.
9. Pierpont GL, DeMaster EG, Reynolds S et al. Ventricular myocardial catecholamines in primates. J Lab Clin Med 1985; 106: 205-210.
10. Petch MC, Nayler WG. Concentration of catecholamines in human cardiac muscle. Br Heart J 1979; 41: 340-344.
11. Wellman HN, Zipes DP. Cardiac sympathetic imaging with radioiodinated metaiodobenzylguanidine (MIBG). Progr Cardiol 1990; 3: 161-174.
12. Sisson JC, Shapiro B, Meyers L et al. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med 1987; 28: 1625-1636.
13. Glowniak JV, Kilty JE, Amara SG. Evaluation of metaiodobenzylguanidine uptake by norepinephrine, dopamine and serotonin transporters. J Nucl Med 1993; 345: 1140-1146.
14. Trendelenburg U. The TiPS lecture: Functional aspests of the neuronal uptake of noradrenaline. Trends Pharmacol Sci 1991; 12: 334-337.
15. Sisson JC, Shapiro B, Meyers L et al. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med 1987; 28: 1625-1636.
16. Jaques S, Tobes MC, Sisson JC, Baker JA, Wieland DM. Comparison of the sodium dependency of uptake of metaiodobenzylguanidine and norepinephrine into cultured bovine adrenomedullary cells. Mol Pharmacol 1984; 26: 539-546.
17. Holzmann H, Schlieter A, Ramirez-Bosca A. Proposal of a revised classification of systemic sclerosis. Eur J Dermatol 1993; 3: 262-265.
18. Slosman DO, Polla BS, Donath A. I-123-MIBG pulmonary removal: A biochemical marker of minimal lung endothelial cell lesions. Eur J Nucl Med 1990; 16: 633-637.
19. Standke R, Hor G. Myocardial scintigraphy with 201-T1: I. Methodology. Nuklearmedizin 1987; 26: 149-154.
20. Estorch M, Carrio I, Lopez-Pousa j et al. Intensity of myocardial MIBG uptake relates to age. Eur J Nucl Med 1994; 8: 787.
21. Pennell JD, Underwood R, Costa DC, Ell PJ. Thallium myocardial perfusion tomography in clinical cardiology. London: Springer-Verlag, 1992: 46-57.
22. Mackel AM, Delustro F, Harper FE, LeRoy EC. Antibodies to collagen in scleroderma. Arthritis Rheum 1982; 25: 522-531.
23. Majewski S, Skopinska-Rozewska E, Jablonska S et al. Modulatory effect of sera from scleroderma patients on lymphocyte-induced angiogenesis. Arthritis Rheum 1985; 28: 1133-1139.
24. Holzmann H, Schlieter A, Altmeyer P, Kühnl P. Immungenetische Untersuchungen bei familiärem Vorkommen von progressiver systemischer Sklerodermie und zirkumskripter Sklerodermie. Hautarzt 1992; 43: 548-553.
25. Rodnan GP, Myerowitz RL, Justh GO. Morphologie changes in the digital artery of patients with progressive systemic sclerosis (scleroderma) and Raynaud’s phenomenon. Medicine 1980; 59: 393-408.
26. Seibold JR, Harris JN. Plasma ß-thromboglobulin in the differential diagnosis of Raynaud’s phenomenon. J Rheumatol 1985; 12: 99-103.
27. Editorial: Endothelins. Lancet 1991; 337: 79-81.
28. LeRoy EC, Trojanowska M, Smith EA. The pathogenesis of scleroderma (systemic sclerosis, SSc). Clin Exp Rheumatol 1991; 9: 173-177.
29. Goldermann R, Kiibler S, Schulte-Huermann P, Goerz G. Das Raynaud Phänomen (RP). H + G 1994; 9: 585-589.
30. Coffman JD. Raynaud’s phenomenon. Hypertension 1991; 17: 593-602.
31. Freedman RR, Sabharwal SC, Desai N, Wenig P, Mayers M. Increased alpha-adrenergic responsiveness in idiopathic Raynaud’s disease. Arthritis Rheum 1989; 32: 61-65.
32. D’Angelo WA, Fries JF, Masi AT et al. Pathologic observations in systemic sclerosis (scleroderm): A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969; 46: 428-440.
33. Gupta MP, Zoneraich S, Zeitlin W et al. Scleroderma heart disease with slow flow velocity in coronary arteries. Chest 1975; 67: 116-119.
34. Anvari A, Graninger W, Schneider B, Sochor H, Weber H, Schmidinger H. Cardiac involvement in systemic sclerosis. Arthritis Rheum 1992; 11: 1356-1361.
35. Clements PJ, Fürst DE, Cabeen W, Tashkin D, Paulus HE, Roberts N. The relationship of arrhythmias and conduction disturbances to other manifestations of cardiopulmonary disease in progressive systemic sclerosis (PSS). Am J Med 1981; 71: 38-46.
36. James TN. Coronary artery and conduction system in scleroderma heart disease. Circulation 1974; 50: 844-856.
37. Ridolfi RL, Bukley BH, Hutchins GM. The conduction system in progressive systemic sclerosis. Am J Med 1976; 61: 361-366.
38. Follansbee WP, Curtiss El, Rahko PS et al. The electrocardiogram in systemic sclerosis (scleroderma): Study of 102 consecutive cases with functional correlations and review of literature. Am J Med 1985; 79: 183-192.
39. Bulkley BH, Klacsmann PG, Hutchins GM. Angina pectoris, myocardial infarction and sudden cardiac death with normal coronary arteries: A clinicopathologic study of 9 patients with progressive systemic sclerosis. Am Heart J 1978; 95: 563-569.
40. Kostis JB, Seibold JR, Turkevich D et al. Prognostic importance of cardiac arrhythmias in systemic sclerosis. Am J Med 1988; 84: 1007-1015.
41. Dessein P, Joffe BI, Metz RM et al. Autonomic dysfunction in systemic sclerosis: Sympathetic overactivity and instability. Am J Med 1992; 93: 143-150.
42. Dart AM, Dietz R, Kübler W et al. Effects of cocaine and desimipramine on the neuronally evoked overflow of endogenous noradrenaline from the rat heart. Br J Pharmacol 1983; 79: 71-74.
43. Zaza A, Schwartz PJ. Role of autonomic nervous system in the genesis of early ischemic arrhythmias. J Cardiovasc Pharmacol 1985; 5: 5-12.
44. Goldstein DS, Brush JE Jr, Eisenhofer G et al. In vivo measurement of neuronal uptake of norepinephrine in the human heart. Circulation 1988; 78: 41-48.
45. Holmgren S, Abrahamsson T, Almgren O et al. Effect of ischemia of the adrenergic neuron on the rat heart: a fluorescence histochemical and biochemical study. Cardiovasc Res 1981; 15: 680-689.
46. Schwaiger M, Guibourg H, Rosenspire K et al. Effect of regional myocardial ischemia on sympathetic nervous system as assessed by fluorine-18-metaraminol. J Nucl Med 1990; 31: 1352-1357.
47. Reimer KA, Jennings RB. The ’wavefront phenomenon’ of myocardial ischemic cell death. Lab Invest 1979; 40: 633-644.
48. Guertner C, Klepzig Jr H, Maul FD et al. Noradrenaline depletion in patients with coronary artery disease before and after percutaneous transluminal coronary angioplasty with iodine 123-metaiodobenzylguanidine and single photon emission tomography. Eur J Nucl Med 1993; 20: 776-782.
49. Inoue H, Zipes DP. Time course of denervation of efferent sympathetic and vagal nerves after occlusion of the coronary artery in the canine heart. Circ Res 1988; 62: 1111-1120.
50. DeBoer FWV, Ingwall JS, Kloner RA, Braunwald E. Prolonged derangement of canine myocardial purine metabolism after a brief coronary artery occlusion not associated with anatomic evidence of necrosis. Proc Nat Acad Sci 1980; 77: 54-71.
51. Deussen A, Henrich M, Harnacher K et al. Noninvasive assessment of regional cardiac adenosine using positron emission tomography. J Nucl Med 1992; 33: 2138-2144.
52. Bailey IA, Seymour A-ML, Radda GK. A 31-P-NMR study of the effects of reflow on the ischemic rat heart. Biochem Biophys Acta 1981; 637: 1-7.
53. Geft IL, Fishbein MC, Ninomya K et al. Intermittent brief periods of ischemia have a cumulative effect and may cause myocardial necrosis. Circulation 1982; 6: 1150-1153.
54. Braunwald E, Kloner RA. The stunned myocardium: prolonged postischemic ventricular dysfunction. Circulation 1982; 6: 1146-1149.
55. Puri PS. Contractile and biochemical effects of coronary reperfusion after extended periods of coronary occlusion. Am J Cardiol 1975; 36: 244.
56. Montanes P, Lawless C, Black C et al. The heart in scleroderma: Noninvasive assessment. Clin Cardiol 1982; 5: 383-387.